Patents by Inventor Mark William Bodmer

Mark William Bodmer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20100303867
    Abstract: A method is provided for reducing an immune response to an allergen or antigenic determinant thereof in a mammal by administering a modulator of the Notch signalling pathway.
    Type: Application
    Filed: April 23, 2010
    Publication date: December 2, 2010
    Inventors: MARK WILLIAM BODMER, EMMANUEL CYRILLE PASCAL BRIEND, BRIAN ROBERT CHAMPION, ANDREW CHRISTOPHER LENNARD, GRAHAME JAMES MCKENZIE, SILVIA RAGNO, TAMARA TUGAL, GEORGE ALBERT WARD, LESLEY LYNN YOUNG
  • Publication number: 20040213797
    Abstract: A conjugate having first and second sequence, wherein the first sequence includes a polypeptide which is capable of binding to a MHC class II molecule and a polypeptide comprising a modulator of the Notch signalling pathway.
    Type: Application
    Filed: January 23, 2004
    Publication date: October 28, 2004
    Inventors: Mark William Bodmer, Brian Robert Champion, Grahame James McKenzie, Lucy Emma Nye
  • Patent number: 6734286
    Abstract: An effective anti-IL-5 recombinant antibody molecule comprising heavy and/or light chain antigen-binding residues from a donor antibody.
    Type: Grant
    Filed: May 15, 2001
    Date of Patent: May 11, 2004
    Assignee: Celltech R&D Limited
    Inventors: Mark William Bodmer, Diljeet Singh Athwal, John Spencer Emtage
  • Publication number: 20030199679
    Abstract: Recombinant, in particular humanised, e.g. humanised chimeric and CDR-grafted humanised, antibody molecules having specificity for human TNF&agr;, are provided for use in diagnosis and therapy. In particular the antibody molecules have antigen binding sites derived from murine monoclonal antibodies CB0006, CB0010, hTNF3 or 101.4. Preferred CDR-grafted humanised anti-hTNF&agr; antibodies comprise variable region domains comprising human acceptor framework and donor antigen binding regions and wherein the frameworks comprise donor residues at specific positions. The antibody molecules may be used for therapeutic treatment of human patients suffering from or at risk of disorders associated with undesirably high levels of TNF, in particular for treatment of immunoregulatory and inflammatory disorders or of septic, endotoxic or cardiovascular shock.
    Type: Application
    Filed: April 22, 2003
    Publication date: October 23, 2003
    Inventors: John Robert Adair, Diljeet Singh Athwal, John Spencer Emtage, Mark William Bodmer
  • Publication number: 20020042089
    Abstract: An effective anti-IL-5 recombinant antibody molecule comprising heavy and/or light chain antigen-binding residues from a donor antibody.
    Type: Application
    Filed: May 15, 2001
    Publication date: April 11, 2002
    Applicant: Celltech Therapeutics Limited.
    Inventors: Mark William Bodmer, Diljeet Singh Athwal, John Spencer Emtage
  • Patent number: 6315999
    Abstract: An antibody to tumor necrosis factor-&agr; (anti-TNF) and an antibody to bacterial lipopolysaccharide (anti-LPS) used together in a neutropenic rat model of sepsis are shown to enhance survival of the rats relative to either antibody used alone. Pharmaceutical products including each of the components are therefore of utility in therapy of sepsis. The anti-LPS antibody included may be specific for the O-specific clain of a particular bacterial lipopolysaccharide (serotype specific antibody) but preferably recognizes the core glycolipid of lipopolysaccharide.
    Type: Grant
    Filed: June 2, 1994
    Date of Patent: November 13, 2001
    Assignee: Solvay, S.A.
    Inventors: Jerald C. Sadoff, Steven Michael Opal, Alan S. Cross, Mark William Bodmer
  • Patent number: 6316227
    Abstract: An effective anti-IL-5 recombinant antibody molecule comprising heavy and/or light chain antigen-binding residues from a donor antibody.
    Type: Grant
    Filed: July 2, 1999
    Date of Patent: November 13, 2001
    Assignee: Celltech Therapeutics Limited
    Inventors: Mark William Bodmer, Diljeet Singh Athwal, John Spencer Emtage
  • Patent number: 6180377
    Abstract: The invention describes humanized antibodies having specificity for the epitope recognised by the murine monoclonal antibody L243. Also described are processes for preparing said antibodies and pharmaceutical compositions and medical uses of said antibodies.
    Type: Grant
    Filed: March 25, 1996
    Date of Patent: January 30, 2001
    Assignee: Celltech Therapeutics Limited
    Inventors: Susan Adrienne Morgan, John Spencer Emtage, Mark William Bodmer, Diljeet Singh Athwal
  • Patent number: 6013642
    Abstract: This invention relates to the use of stroid sulphate sulphatase inhibitors which prevent the normal physiological effect of DHEA or related steroids on inflammatory responses.
    Type: Grant
    Filed: April 14, 1997
    Date of Patent: January 11, 2000
    Inventors: Roland Foulkes, John Spencer Emtage, Mark William Bodmer, Martin Rae Wales, Graham Arthur William Rook
  • Patent number: 5998586
    Abstract: An effective anti-IL-5 recombinant antibody molecule comprising heavy and/or light chain antigen-binding residues from a donor antibody.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: December 7, 1999
    Assignee: Celltech Therapeutics, Limited
    Inventors: Mark William Bodmer, Diljeet Singh Athwal, John Spencer Emtage
  • Patent number: 5994510
    Abstract: Recombinant, in particular humanised, e.g. humanised chimeric and CDR-grafted humanised, antibody molecules having specificity for human TNF.alpha., are provided for use in diagnosis and therapy. In particular, the antibody molecules have antigen binding sites derived from murine monoclonal antibodies CB0006, CB0010, hTNF3 or 101.4. Preferred CDR-grafted humanised anti-hTNF.alpha. antibodies comprise variable region domains comprising human acceptor framework and donor antigen binding regions and wherein the frameworks comprise donor residues at specific positions. The antibody molecules may be used for therapeutic treatment of human patients suffering from or at risk of disorders associated with undesirably high levels of TNF, in particular for treatment of immunoregulatory and inflammatory disorders or of septic, endotoxic or cardiovascular shock.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: November 30, 1999
    Assignee: Celltech Therapeutics Limited
    Inventors: John Robert Adair, Diljeet Singh Athwal, John Spencer Emtage, Mark William Bodmer
  • Patent number: 5965405
    Abstract: Methods for preparing Fv fragments which lack linking polypeptides in eukaryotic cells are provided.
    Type: Grant
    Filed: December 13, 1993
    Date of Patent: October 12, 1999
    Assignee: Celltech Limited
    Inventors: Gregory Paul Winter, Lutz Riechmann, Geoffrey Thomas Yarranton, Mark William Bodmer, Raymond John Owens
  • Patent number: 5958413
    Abstract: A combined preparation for simultaneous combined, simultaneous separate, or sequential use in the therapy of prophylaxis of disorders associated with undesirable high levels of TNF, e.g. septic or endotoxic shock and immunoregulatory and inflammatory disorders, which comprises an antibody to TNF or a TNF binding fragment thereof and a xanthine derivative. Particular preferred xanthine derivatives are 3,7-dimethyl-1(5-oxo-hexyl)xanthine (known as Pentoxifylline or TRENTAL) and 1-(5-hydroxy-5-methylhexyl)-3-methylxanthine and similar compounds. The anti-TNF antibody or fragment is preferably monospecific especially a humanized recombinant antibody or fragment.
    Type: Grant
    Filed: November 10, 1997
    Date of Patent: September 28, 1999
    Assignees: Celltech Limited, Hoechst Aktiengesellschaft
    Inventors: Hiristo Anagnostopulos, Ulrich Gebert, Heinz Hanel, Michael Limbert, Mark William Bodmer, Gerald Anthony Higgs
  • Patent number: 5877293
    Abstract: The present invention provides humanized antibody molecules (HAMs) having specificity for carcinoembryonic antigen (CEA) and having an antigen binding site wherein at least one of the complementarity determining regions (CDRs) of the variable domains is derived from the mouse monoclonal antibody A5B7 (A5B7 MAB) and the remaining immunoglobulin-derived parts of the HAM are derived from a human immunoglobulin. The HAMs may be chimeric humanized antibodies or CDR-grafted humanized antibodies and are preferably produced by recombinant DNA techniques. The HAMs are useful for in vivo diagnosis and therapy.
    Type: Grant
    Filed: May 24, 1995
    Date of Patent: March 2, 1999
    Assignee: Celltech Therapeutics Limited
    Inventors: John Robert Adair, Mark William Bodmer, Andrew Mountain, Raymond John Owens
  • Patent number: 5677425
    Abstract: The present invention provides an altered antibody molecule (AAM) having a hinge region which has a different number of cysteine residues from that found in the hinge region normally associated with the CH1 domain of the antibody molecule and a process for producing the same using recombinant DNA technology.
    Type: Grant
    Filed: August 18, 1994
    Date of Patent: October 14, 1997
    Assignee: Celltech Therapeutics Limited
    Inventors: Mark William Bodmer, John Robert Adair, Nigel Richard Whittle
  • Patent number: RE39548
    Abstract: An effective anti-IL-5 recombinant antibody molecule comprising heavy and/or light chain antigen-binding residues from a donor antibody.
    Type: Grant
    Filed: December 7, 2001
    Date of Patent: April 3, 2007
    Assignee: Celltech R&D Limited
    Inventors: Mark William Bodmer, Diljeet Singh Athwal, John Spencer Emtage